Blog

Home  /  Covid-19   /  RCR01-RCR15 Covid-19 Rolling Collaborative Review – Second round of reviews now available

RCR01-RCR15 Covid-19 Rolling Collaborative Review – Second round of reviews now available

As part of its response to the Covid-19 pandemic, EUnetHTA is working to output ‘Rolling Collaborative Reviews (RCR)’. The objective of such reviews is to provide decision-makers with a timely synthesis of available evidence on the comparative effectiveness of therapeutic health technologies relevant to the management of the current pandemic.

EUnetHTA is pleased to announce that the second round of these monthly updated Covid-19 Rolling Collaborative Reviews (RCR) is now available.

Please access the reviews, together with the project description and planning, here:

RCR01-RCRXX – Project Description and Planning

RCR01: Convalescent Plasma Treatment

RCR02: Lopinavir + Ritonavir (Kaletra©)

RCR03: Tocilizumab (RoActemra©)

RCR04: Camostat (Foipan©)

RCR05: Nafamostat (Futhan©)

RCR06: Solnatide

RCR07: Anakinra

RCR08: Dexamethasone

RCR09: APN01 (rhACE2)

RCR10: Darunavir (Prezista©)

RCR11: Favipiravir (Avigan©)

RCR12: Sarilumab (Kevzara©)

RCR13: Interferon beta 1a

RCR14: Gimsilumab

RCR15: Canakinumab